Rockefeller Capital Management
SIOX

Rockefeller Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Rockefeller Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-312
Closed – – 4507
2022
Q1 		$0 Hold
312
– – ﹤0.01% 4151
2021
Q4 		$0 Hold
312
– – ﹤0.01% 4065
2021
Q3 		$0 Hold
312
– – ﹤0.01% 3911
2021
Q2 		$0 Buy
+312
New +$776 ﹤0.01% 3663

Other funds holding SIOX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rockefeller Capital Management's SIOX Position: Q2 2022 in Review

Rockefeller Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2022, closing a stake of 312 shares.

Rockefeller Capital Management first reported a position in SIOX in Q2 2021 and held it in 4 quarters. The position peaked at $0 in Q1 2022. 41 funds tracked by Wall St. Rank hold SIOX as of Q2 2022.

  • Rockefeller Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 312 Sio Gene Therapies Inc. Common Stock shares in Q2 2022.
  • Rockefeller Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Rockefeller Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $0 in Q1 2022.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2022.

Based on Rockefeller Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.